Program Description
Triple-negative breast cancer (TNBC) tumors lack expression of estrogen, progesterone, and human epidermal growth factor 2 (HER2) receptors and are therefore not sensitive to endocrine therapy or HER2-directed treatment. Targeted treatments, including existing immunotherapy agents and a novel antibody-drug conjugate (ADC) have improved progression-free survival in metastatic TNBC. As additional therapies are approved for metastatic TNBC and treatment algorithms and recommendations evolve, pharmacists involved in managed care must ensure clinical treatment pathways are reviewed and amended and patients with TNBC have access to and are receiving emerging therapies. This activity will focus on systemic management tools to both improve patient outcomes and reduce healthcare resource utilization in TNBC. Strategies outlined will include the implementation and maintenance of oncology clinical pathways as well as approaches to ensure adherence to clinical pathways and delivery of cost-effective, clinically appropriate care for patients with metastatic TNBC.
Target Audience: Managed care pharmacists and oncology pharmacists
Type of Activity: Application
Release date: July 21, 2022
Expiration date: September 21, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the impact of recent immune checkpoint inhibitor and antibody-drug conjugate clinical trials on the current landscape and treatment guidelines for metastatic triple-negative breast cancer (mTNBC).
- Investigate utilization management strategies to optimize accessibility of therapies for the treatment of mTNBC.
- Identify the roles of managed care pharmacists in the implementation and optimization of formulary changes for the treatment of mTNBC.
Laura R. Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Plantation, Florida
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-296-L01-P. The activity is available for CE credit through September 21, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Laura R. Bobolts, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Disclosure Policy
According to the disclosure policy of The American Journal of Managed Care® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Disclosure of Unapproved/Off-Label Use
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.
The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care®, Pharmacy Times Continuing Education™, or any of the companies that provided commercial support for this CE activity.
Signed disclosures are on file at the office of The American Journal of Managed Care®, Cranbury, New Jersey.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms